The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. (Q50237958)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 February 2013

Language	Label	Description	Also known as
English	The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.	scientific article published on 12 February 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Kunio Matsumoto

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Takako Sano

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Shinji Takeuchi

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Takayuki Nakagawa

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Daisuke Ishikawa

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Shigeki Nanjo

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Takahiro Nakamura

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Seiji Yano

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

0 references

publication date

12 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

133

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

505-513

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor–Activating Mutations

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Oncogenic PI3K deregulates transcription and translation

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Targeting the phosphoinositide 3-kinase pathway in cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

The PI3K pathway as drug target in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

The TOR pathway: a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

The pharmacology of mTOR inhibition

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28034

21 January 2018

Identifiers

10.1002/IJC.28034

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319394%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50237958&oldid=2249132145"